DIFFUSION PHARMACEUTICALS IN (DFFN)

Company Profile

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The company is headquartered in Charlottesville, Virginia and currently employs 13 full-time employees. The company went IPO on 2016-11-09. The firm is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s intractable and difficult-to-treat conditions, including hypoxic solid tumors, such as GBM. TSC is the therapeutic candidate specifically designed to enhance the oxygen diffusion process. By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system. Hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.

Company Info

DIFFUSION PHARMACEUTICALS IN

300 East Main Street, Suite 201

Charlottesville VIRGINIA 22902

P: 14342200718.0

CEO: Robert J. Cobuzzi

Employees: 13

Website: https://diffusionpharma.com/